Trial intelligence / Profile preview

TAK-788 versus platinum-based chemotherapy as first-line treatment for EGFR exon 20 insertion NSCLC

NL-OMON54828Phase 3Completed

Sponsor

Takeda

Start

Feb 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1